Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 15/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13773081 | 0.82 | HRH3 (0.69) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3090947 | 0.80 | HRH3 (0.53) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL167108 | 0.80 | HRH3 (0.68) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL1791095 | 0.79 | ALDH1A1 (0.42) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL1707159 | 0.79 | HRH3 (1.00) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3695532 | 0.79 | HRH3 (0.66) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3086218 | 0.79 | HRH3 (0.52) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3694737 | 0.79 | HRH3 (0.65) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3089908 | 0.79 | PDE4B (0.48) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL27549464 | 0.79 | OPRM1 (0.69) | HRH3OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | claimed |
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | claimed |
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | claimed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | claimed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | claimed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | claimed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
| EP-2133340-B1 | Novel benzazepine derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| US-8288389-B2 | Piperazine derivative having affinity for the histamine H3 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2195307-B1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2012-04-18 | — | — | EP | disclosed |
| US-20100204242-A1 | Piperazine Derivative Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| EP-2133340-A1 | Novel benzazepine derivatives | Glaxo Group Limited (GB) | 2009-12-16 | — | — | EP | disclosed |
| US-7560453-B2 | 6-(2, 3, 4, 5-tetrahydro-1H-benzo [D] azepin-7-yloxy) -nicotamide derivatives as radio labelled ligands | GLAXO GROUP LIMITED (GB) | 2009-07-14 | — | — | US | disclosed |
| US-20090170869-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | disclosed |
| US-20080166298-A1 | 6- (2, 3, 4, 5-Tetrahydro-1H-Benzo [D] Azepin-7-Yloxy) -Nicotamide Derivatives as Radio Labelled Ligands | GLAXO GROUP LIMITED | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170869-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885OPRM1 412/4885OPRD1 528/4885 |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | HRH3 211/4885OPRM1 268/4885OPRD1 47/4885 |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885OPRM1 794/4885OPRD1 309/4885 |
| US-20100204242-A1 | Piperazine Derivative Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH1 | HRH3 1/4885OPRM1 412/4885OPRD1 528/4885 |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885OPRM1 794/4885OPRD1 309/4885 |
| US-20080166298-A1 | 6- (2, 3, 4, 5-Tetrahydro-1H-Benzo [D] Azepin-7-Yloxy) -Nicotamide Derivatives as Radio Labelled Ligands | HRH3, HRH4, HRH1 | HRH3 1/4885OPRM1 185/4885OPRD1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.